Albemarle Corporation
ALB
$117.64
-0.10%
Albemarle Corporation is one of the world's largest lithium producers, fully integrated from upstream salt brine and hard rock mining to downstream refining, serving the battery and electric vehicle supply chain. As a global leader in lithium and bromine, it holds a distinct competitive position due to its scale, low-cost resources, and strategic joint ventures in Chile, Australia, and the US. The current investor narrative centers on a sharp lithium price downturn that has crushed near-term profitability, yet the stock has rallied 36% over the past year on expectations of a cyclical recovery and long-term EV demand growth. Recent news highlights a potential lithium-fueled rebound, with analysts debating whether the recent pullback offers a value entry point or signals further downside.…
ALB
Albemarle Corporation
$117.64
Related headlines
Investment Opinion: Should I buy ALB Today?
Rating: Buy. Thesis: Albemarle offers a compelling risk/reward for investors bullish on the lithium cycle, with a strong Q1 2026 earnings turnaround, accelerating revenue growth, and a low PEG ratio, supported by a consensus Buy rating and average target price of $187.91 implying 63.6% upside.
Supporting Evidence: The primary valuation metric is the forward PS ratio of 2.25, which is below the trailing PS of 3.24 and implies expected revenue growth. Revenue grew 32.7% YoY in Q1 2026, and gross margin improved to 35.1% from 14.2% in Q4 2025. Free cash flow turned positive at $248 million in Q1 2026. The PEG ratio of 0.51 suggests undervaluation relative to forward earnings growth. Compared to the industry average PS of 1.5x, Albemarle trades at a premium, but this is justified by its dominant position in a high-growth end market.
Risks & Conditions: The biggest risks are a reversal in lithium prices, which could compress margins and push the company back to losses, and the premium valuation that leaves little room for error. This Buy rating would be downgraded to Hold if lithium prices fall 20% or more from current levels, or if Q2 2026 earnings show a sequential decline in gross margin below 25%. It would be upgraded to Strong Buy if the stock pulls back to $100 or below while fundamentals remain intact. Overall, Albemarle appears undervalued relative to its forward earnings potential but fairly valued on a historical PS basis, making it a buy for those with a high risk tolerance and a long-term horizon.
Sign up to view all
ALB 12-Month Price Forecast
The AI assessment leans bullish on Albemarle, driven by the strong Q1 2026 earnings turnaround and accelerating revenue growth. The low PEG ratio and positive free cash flow support the view that the stock is undervalued relative to its earnings potential. However, confidence is medium due to the high volatility and dependence on lithium prices, which remain unpredictable. The stance would be upgraded to high confidence if the company delivers another quarter of sequential margin improvement and if lithium prices show a sustained upward trend. Conversely, a downgrade to neutral would occur if Q2 2026 earnings disappoint or if lithium prices break below recent lows.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Albemarle Corporation's 12-month outlook, with a consensus price target around $187.16 and implied upside of +59.1% versus the current price.
Average Target
$187.16
0 analysts
Implied Upside
+59.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$83 - $250
Analyst target range
Albemarle is covered by 20 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.95 on a 1-5 scale, where 1 is strong buy). The average target price is $187.91, implying a substantial 63.6% upside from the current price of $114.85. The distribution shows a bullish lean, with recent upgrades from Citigroup (to Buy) and maintained Outperform ratings from RBC Capital and Scotiabank. The target range spans from a low of $83.28 to a high of $250.00, indicating significant uncertainty. The high target of $250 assumes a strong lithium price recovery and multiple expansion, while the low target of $83.28 prices in continued margin compression and potential competitive losses. The wide spread (over 200% between low and high) reflects the high uncertainty around lithium prices and the cyclical nature of the business. Recent ratings actions show a mix of upgrades and neutral stances, with Mizuho maintaining Neutral and Wells Fargo at Equal Weight, suggesting some caution. Overall, the consensus is bullish but with a wide range of outcomes, implying that investors should expect high volatility and monitor lithium market dynamics closely.
Drowning in data?
Find the real signal!
Bulls vs Bears: ALB Investment Factors
Albemarle presents a high-risk, high-reward opportunity tied to the lithium cycle. The bull case is supported by a strong Q1 2026 earnings rebound, accelerating revenue growth, and a low PEG ratio, with analysts seeing 63.6% upside. However, the bear case highlights negative trailing profitability, extreme volatility, and a premium valuation that depends on a sustained lithium price recovery. The single most important tension is whether the Q1 2026 profitability improvement is the start of a sustained uptrend or a temporary reprieve in a volatile commodity cycle. Currently, the evidence slightly favors the bulls given the strong operational turnaround and analyst consensus, but the wide target range underscores the need for caution.
Bullish
- Strong Q1 2026 Earnings Rebound: Albemarle reported Q1 2026 net income of $319 million, swinging from a loss of $414 million in Q4 2025, with EPS of $2.35. This dramatic turnaround demonstrates the company's operating leverage and ability to generate profits when lithium prices stabilize.
- Significant Upside to Analyst Targets: The average analyst price target is $187.91, implying a 63.6% upside from the current price of $114.85. The high target of $250 suggests potential for more than a double, reflecting strong conviction in a lithium cycle recovery.
- Revenue Growth Accelerating: Q1 2026 revenue grew 32.7% year-over-year to $1.43 billion, driven by higher lithium volumes and pricing. This marks a sharp acceleration from the prior year's declines and signals improving demand fundamentals.
- Low PEG Ratio Suggests Undervaluation: The PEG ratio of 0.51, based on forward earnings estimates, indicates the stock is undervalued relative to its expected earnings growth. This is well below the typical threshold of 1.0 for fair value.
Bearish
- Negative Trailing EPS and ROE: Trailing twelve-month EPS is -$0.03, and ROE is -5.4%, reflecting the impact of prior losses. Despite the Q1 rebound, profitability on a trailing basis remains negative, highlighting the cyclical risk.
- Extreme Price Volatility and Drawdown: The stock has a beta of 1.35 and a 52-week range of $64.95 to $221.00, with a max drawdown of -46.73%. The recent 3-month decline of -39% shows how quickly sentiment can shift.
- Premium Valuation vs. Peers: The trailing PS ratio of 3.24 is more than double the specialty chemicals industry average of ~1.5x. This premium embeds high expectations for a lithium recovery, leaving little room for disappointment.
- Dependence on Lithium Price Recovery: Albemarle's profitability is highly sensitive to lithium prices. The Q1 2026 gross margin of 35.1% improved from 14.2% in Q4 2025, but any reversal in lithium prices could quickly erode margins and push the company back to losses.
ALB Technical Analysis
Albemarle is in a sustained uptrend over the past year, with a 1-year price change of +36.4%, but the stock has experienced a severe pullback from its 52-week high of $221.00. Currently trading at $114.85, it sits at just 52% of its 52-week range, near the low end, suggesting the stock is deeply oversold and potentially offering a value opportunity if the fundamental thesis holds. The 52-week low of $64.95 provides a stark contrast, indicating extreme volatility and the risk of further downside if lithium prices deteriorate further. Short-term momentum is decisively bearish, with the 1-month price change of -22.3% and 3-month change of -39.0% sharply diverging from the positive 1-year trend. This divergence signals a potential trend reversal or a temporary pullback within a longer-term recovery, but the magnitude of the decline suggests a loss of investor confidence. The relative strength index (RSI) is not provided, but the steep drop implies oversold conditions, which could attract contrarian buyers. The 52-week high of $221.00 acts as a major resistance level; a breakout above this would signal a resumption of the uptrend and could target new highs. Conversely, the 52-week low of $64.95 is the key support; a breakdown below this level would likely trigger further selling and confirm a bearish trend. With a beta of 1.35, Albemarle is 35% more volatile than the S&P 500, meaning it amplifies market moves—a factor that increases risk for position sizing and requires tighter stop-losses.
Beta
1.35
1.35x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$65-$221
Price range past year
Annual Return
+73.4%
Cumulative gain past year
| Period | ALB Return | S&P 500 |
|---|---|---|
| 1m | -13.6% | +0.2% |
| 3m | -39.3% | +3.7% |
| 6m | -31.1% | +8.0% |
| 1y | +73.4% | +18.2% |
| ytd | -18.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALB Fundamental Analysis
Revenue has shown a mixed trajectory: the most recent quarter (Q1 2026) reported revenue of $1.429 billion, up 32.7% year-over-year, a strong acceleration from the prior year's declines. However, the trailing twelve months show revenue of approximately $5.49 billion, with the Energy Storage segment (lithium batteries) contributing $891 million in Q1 2026, up significantly, while Specialties added $358 million. The growth is driven by higher lithium volumes and pricing, but the cyclical nature of lithium prices creates uncertainty. The company swung to a net income of $319 million in Q1 2026 from a loss of $414 million in Q4 2025, but the trailing twelve months net income is negative at -$0.03 per share. Gross margin improved dramatically to 35.1% in Q1 2026 from 14.2% in Q4 2025, indicating cost control and better pricing, but the operating margin of 16.3% is still below historical highs. The net margin of 22.3% in Q1 2026 is positive, but the overall profitability remains fragile and dependent on lithium prices. Albemarle's balance sheet shows a debt-to-equity ratio of 0.35, which is moderate, and a current ratio of 2.23, indicating ample liquidity. Free cash flow was $248 million in Q1 2026, a strong improvement from negative free cash flow in prior quarters, suggesting the company is generating cash to fund operations. However, the ROE is negative at -5.4% over the trailing twelve months, reflecting the impact of recent losses. The company has $1.09 billion in cash, providing a cushion against further downturns, but capital expenditures remain high, requiring sustained cash generation.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+32.7%
YoY Comparison
Gross Margin
35.1%
Latest Quarter
Free Cash Flow
$577275000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALB Overvalued?
Since net income is negative on a trailing twelve-month basis (EPS -$0.03), the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 3.24, while the forward PS (based on estimated revenue of $7.40 billion) is approximately 2.25, implying the market expects significant revenue growth. The gap between trailing and forward PS suggests optimism about a recovery. Compared to the specialty chemicals industry average PS of around 1.5x (estimated), Albemarle trades at a 116% premium, reflecting its lithium-focused growth profile. This premium is justified by its dominant position in a high-growth end market (EV batteries) and its integrated low-cost structure, but it also embeds high expectations. Historically, Albemarle's PS ratio has ranged from below 2x in 2021 to over 30x in 2021-2022. At 3.24x, the current PS is near the lower end of its historical range, suggesting the stock is relatively cheap compared to its own history. However, the historical low PS of around 1.5x in 2021 indicates that further compression is possible if lithium prices remain depressed. The PEG ratio of 0.51 (based on forward earnings) suggests the stock is undervalued relative to its expected earnings growth, but this relies on a sharp earnings rebound.
PE
-24.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
32.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Albemarle's financial performance is highly cyclical, as evidenced by trailing twelve-month net income of -$0.03 per share and a negative ROE of -5.4%. The company swung from a net loss of $414 million in Q4 2025 to a profit of $319 million in Q1 2026, demonstrating extreme earnings volatility tied to lithium prices. While the balance sheet is healthy with a debt-to-equity ratio of 0.35 and $1.09 billion in cash, the company's capital-intensive operations require sustained positive free cash flow, which was $248 million in Q1 2026 but negative in prior quarters. Margin pressure remains a key risk: gross margin improved to 35.1% in Q1 2026 but was as low as 14.2% in Q4 2025, and operating margin of 16.3% is still below historical highs.
Market & Competitive Risks: Albemarle trades at a trailing PS ratio of 3.24, a 116% premium to the specialty chemicals industry average of ~1.5x, leaving it vulnerable to valuation compression if growth disappoints. The stock's beta of 1.35 indicates 35% higher volatility than the market, amplifying macro risks such as rising interest rates or a recession that could slow EV adoption. Competitive risks include potential oversupply from new lithium producers and technological shifts in battery chemistry. Recent news highlights a lithium-fueled rebound narrative, but the stock's 3-month decline of -39% shows how quickly sentiment can sour on commodity price weakness.
Worst-Case Scenario: In a prolonged lithium price downturn, Albemarle could return to negative free cash flow and face margin compression, potentially triggering analyst downgrades and a re-rating to a PS ratio closer to its historical low of 1.5x. This scenario could drive the stock down to the 52-week low of $64.95, representing a -43.5% decline from the current price of $114.85. The analyst low target of $83.28 implies a -27.5% downside, but if lithium prices collapse further, losses could exceed 50% from current levels.
FAQ
The primary risk is lithium price volatility, which directly impacts profitability. In Q1 2026, gross margin improved to 35.1%, but it was as low as 14.2% in Q4 2025, showing how quickly margins can compress. Second, the stock's beta of 1.35 means it amplifies market moves, and the 52-week range of $64.95 to $221.00 highlights extreme price swings. Third, the premium valuation (PS 3.24 vs. industry 1.5) leaves little room for error; if lithium prices disappoint, the stock could re-rate lower. Finally, competitive risks include new lithium supply and potential battery technology shifts. The most severe risk is a prolonged downturn that could push the stock back to its 52-week low of $64.95, a 43.5% decline from current levels.
The 12-month outlook is bullish but uncertain. The base case (45% probability) sees the stock trading between $140 and $187.91, driven by stable lithium prices and gradual margin recovery. The bull case (30% probability) targets $187.91 to $250, assuming a strong lithium rebound and margin expansion. The bear case (25% probability) sees the stock falling to $64.95-$83.28 if lithium prices decline further. The AI assessment is bullish with medium confidence, citing the Q1 2026 earnings turnaround and low PEG ratio. The most likely scenario is the base case, where the stock appreciates toward the average analyst target of $187.91 over the next 12 months.
Albemarle's valuation is mixed. On a trailing PS basis of 3.24, it trades at a 116% premium to the specialty chemicals industry average of ~1.5x, suggesting it is overvalued relative to peers. However, the forward PS ratio of 2.25 is lower, reflecting expected revenue growth. The PEG ratio of 0.51 indicates the stock is undervalued relative to its expected earnings growth, and the forward PE of 9.18 is low for a company with strong growth prospects. Historically, ALB's PS ratio has ranged from below 2x to over 30x, so the current level is near the lower end of its historical range. Overall, the market is pricing in a recovery, but the premium to peers implies high expectations.
Albemarle presents a high-risk, high-reward opportunity. The stock has rallied 36% over the past year but has pulled back 39% in the last three months, currently trading at $114.85. Analysts see 63.6% upside to the average target of $187.91, and the PEG ratio of 0.51 suggests undervaluation relative to forward earnings. However, the trailing PS ratio of 3.24 is a premium to the industry average, and the stock is highly volatile with a beta of 1.35. For investors with a high risk tolerance and a long-term view on lithium demand, ALB could be a good buy at current levels. However, those seeking stable income or low volatility should look elsewhere.
Albemarle is better suited for long-term investment (3-5 years) due to its cyclical nature and high volatility. The stock has a beta of 1.35 and has experienced a max drawdown of -46.73%, making it risky for short-term traders. The dividend yield is 2.15%, providing some income, but the payout ratio is negative, indicating dividends are not well-covered. Long-term investors can benefit from the secular growth in EV demand and lithium's critical role, but they must tolerate significant price swings. Short-term trading is possible given the stock's volatility, but it requires active monitoring of lithium prices and earnings reports. A minimum holding period of 3 years is recommended to ride out the commodity cycle.
